Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

HOME >> API >> API List 3 >> Ondansetron Base >> Interaction

INTERACTION
Ondansetron Base CAS number 116002-70-1

Before receiving ondansetron, tell your doctor if you are using any of the following drugs:

*phenytoin (Dilantin), phenobarbital (Luminal);
*carbamazepine (Carbatrol, Tegretol);
*tramadol (Ultram); or
*rifampin (Rifadin, Rimactane, Rifater).

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liverBecause ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol

Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.

In a crossover study in 76 pediatric patients, I.V. ondansetron did not increase blood levels of high- dose methotrexate.

Information Associated with Product:
DRUG DESCRIPTION DOSAGE SIDE EFFECTS PRECAUTIONS INTERACTION >> CONSUMER INFORMATION
PDF DOWNLOAD	WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order

Investor Relations    Feedback     Contact Worldwide    Sitemap